Predictive Risk-scoring Model For Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma

Lie-hao Jiang1,4, Ke-xin Yin3,4, Qing-liang Wen6,4, Chao Chen2, Ming-hua Ge1* & Zhuo tan1*

There are about half of papillary thyroid carcinoma (PTC) patients with the experience of central lymph node metastasis (CLNM), while the model to predict high-risk groups of CLNM from PTC patients is uncertain. The aim of this study was to evaluate candidate risk factors of CLNM and identify risk factors of recurrence to guide the postoperative therapeutic decision and follow-up for physicians and patients. A total of 4107 patients (4884 lesions) who underwent lymph node dissection in two hospitals from 2005 to 2014 were evaluated. CLNM risk was stratified and a risk-scoring model was developed on the basis of the identified independent risk factors for CLNM. The Cox's proportional hazards regression model was used to investigate the risk factors for recurrence. CLNM was proved in 37.96% (1559/4107) of patients and 33.96% (1659/4884) of lesions. In the multivariate analysis, Male, Age ≤ 35 years, Tumor size >0.5 cm, Lobe dissemination (+), Psammoma body (+), Multifocality and Capsule invasion (+) were independent risk predictors of CLNM (p < 0.01). A 14-point risk-scoring model was built to predict the stratified CLNM in PTC patients and the area under receiver operating characteristic curve of the model for the prediction of CLNM was 0.672 (95% CI: 0.656–0.688) (P < 0.01). COX regression model showed that Tumor size >0.5 cm, Lobe dissemination (+), Multifocality and CLNM were significant risk factors associated with poor outcomes. The research suggested that prophylactic CLN dissection could be performed in patients with total score ≥4 according to the risk-scoring model, and more aggressive treatment and more frequent follow-up should be considered for patients with Tumor size >0.5 cm, Lobe dissemination (+), Multifocality and CLNM.

In current years, the global prevalence of thyroid cancer has increased swiftly. In 2012, thyroid cancer even has exceeded breast carcinoma as the most prevalent carcinoma of women in Hangzhou, China1. Papillary thyroid carcinoma (PTC) is the most well-known type of thyroid cancer, making up about 85% of thyroid cancer, and constituting 1% of whole human malignant tumors2,3. Notwithstanding the extraordinary rate of the 5-year disease-specific survival rate in the excellent prognosis of PTC, which usually can reach 99%, half of PTC patients have suffered from cervical lymph node metastasis4. Even in the clinical lymph node negative patients, the rate of cervical lymph node metastasis ranges from 20–50% in different studies5,6.

There is still no uniform professional guidelines for cervical lymph node dissection and whether prophylactic cervical lymph node dissection is needed remains controversial. Central compartment was regarded as the most common compartment involved and the American Thyroid Association (ATA) Guidelines recommend that prophylactic central lymph node dissection can be taken into consideration, particularly for the patients who have advanced primary tumors (T3 or T4), and at the meantime ATA does not promote the prophylactic lateral lymph node dissection7. Some scholars considered that a prophylactic central lymph node (CLN) dissection alone for thyroid carcinoma may increase the complications and has weak connection with improve survival8. However, advanced proof from a large scale nested case-control study proposed that patients with lymph node metastasis

1Department of Head, Neck and Thyroid Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, 158 Shangtang Road, Xiacheng District, Hangzhou, 310014, China. 2Department of Head and Neck Surgery, Zhejiang Cancer Hospital, 1 East Banshan Road, Gongshu District, Hangzhou, 310016, China. 3Second Clinical Medical College, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou, 310022, China. 4These authors contributed equally: Lie-hao Jiang, Ke-xin Yin, and Qing-liang Wen.

*email: geminghua@hmc.edu.cn; tanzhuoyue@163.com
experienced a higher mortality, and the incomplete surgical excision was a primary cause for the heightened mortality in PTC patients.

Currently, due to the limitation of clinical examinations, it is hard to find subclinical lymph node metastasis in PTC patients, which may cause incomplete clinical treatment and seriously threaten the health of the patients. Therefore, it has become increasingly important for us to discover appropriate clinical and pathological predictors of lymph node metastasis to guide treatment decisions. Hitherto, a number of possible risk factors have been reported, while the results differ from each other and further investigation is warranted.

This study aimed to retrospectively analyze the clinical and pathological data of PTC sufferers diagnosed between 2005 and 2014 to estimate the applicant risk factors of CLNM and create a model based on those factors to predict high-risk groups of CLNM from PTC patients. We also gathered data on prognosis in order to recognize risk factors of recurrence, which may offer guidance on the postoperative therapeutic decision and follow-up for physicians and patients.

Materials and Methods

Patient selection. This retrospective study was approved by the Ethics Committee of Zhejiang Cancer Hospital and the Ethics Committee of Zhejiang Provincial People’s Hospital. The informed consent was obtained from the patients. The study was performed in accordance with established national and institutional ethical guidelines on the human participants and the use of tissue samples for research. A total of 4107 patients (4884 lesions) who were first treated in the two hospitals between January 2005 and December 2014 were evaluated retrospectively. All the patients were diagnosed as PTC on pathology. Patients with one or more of the following will be excluded: i) patients with previous thyroid resection at another institution; ii) patients with other malignancies; iii) patients with a history of neck surgery for other diseases.

Preoperative ultrasonography examination and Surgical strategy. All patients in the study underwent ultrasonography (US) examination pre-operation to determine the lymph node status. Tumor number was as well as based on preoperative US examination and lesions were divided into Solitary group with only one nodule or Multifocality group with more than one nodule.

Total thyroidectomy and bilateral CLN dissection was performed in the patients with bilateral PTC, while the patients with unilateral PTC underwent total thyroidectomy or unilateral lobectomy plus isthmusectomy and ipsilateral CLN dissection depending on the condition of the primary tumor. Total thyroidectomy plus isthmusectomy might be considered when unilateral PTC patients met one or more of following conditions: (i) tumor size >4 cm; (ii) multifocal in one lobe; (iii) extrathyroid invasion, or (iv) distant metastasis, according to the guidelines of Chinese Thyroid Association. All the patients underwent ipsilateral prophylactic CLN dissection including the pretracheal and paratracheal nodes, precricoid nodes, and the perihypothyroidal nodes including the lymph nodes along the recurrent laryngeal nerves.

Grouping. There were 777 patients with bilateral lesions and 3330 patients with unilateral lesions. All the bilateral lesions were regarded as independent lesions and a total of 4884 lesions included in the group. The patients who underwent lymph node dissection were grouped according to Tumor number, Lobe dissemination, Psammoma body, Capsule invasion (Table 1). Tumor size was decided by the maximum diameter of the tumor by the preoperative ultrasonoscopy. Tumor number was decided by the preoperative ultrasonoscopy. Capsule invasion, Lobe dissemination, Psammoma body data for Predictive Risk-scoring Model were based on intraoperative frozen-section examination results and confirmed by paraffin-section post-operation.

Follow-up and postoperative treatment. The time points of follow-up were 3, 6, 9, 12, 18, 24, 36, 48 and 60 months after surgery. Recurrence was defined as any new lesions detected clinically or radiographically after surgery. Disease-free survival (DFS) was the duration started from the surgery to recurrence or to the date of most recent follow-up. Overall survival (OS) was the duration started from the surgery to death or to the date of most recent follow-up.

TSH suppression therapy was conventionally performed in PTC patients postoperatively. Postoperative RAI ablation therapy would be performed in patients with total thyroidectomy and one or more of the following conditions: (i) T3 or T4; (ii) positive lateral lymph node metastasis; (iii) distant metastasis. Patients underwent a conventional US examination every 3 months to detect local recurrence and computer tomography (CT) examination of chest every year to detect lung metastasis. Every recurrence in remnant thyroid gland or regional lymph nodes was diagnosed by US and confirmed by fine needle aspiration or histological examination post-operation. Distant metastasis was diagnosed by CT and RAI scintigraphy after completion total thyroidectomy.

Statistics analysis. Statistical Package for Social Sciences (SPSS, Inc, Chicago, IL, USA) was used for Statistics analysis. Univariate analysis was performed using chi-square criterion while multivariate analysis was performed using logistic regression analysis. Multiple testing issue was considered when age and tumor size were compared in several groups. A scoring model was constructed to further display the relationships among factors and probability of CLNM. The score of each risk factor was weighted according to the beta coefficient obtained from the logistic regression model. For convenience, all the beta coefficient divided the least one and then rounded to the nearest whole number to keep the scoring model simple. The total score for each patient represented the sum of scores for each risk factor and a risk-scoring model was built to predict the stratified CLNM in PTC patients. To evaluate the predictive performance of the scoring model and find a appropriate cut-off point, we adopted the receiver operating characteristic curve (ROC curve) and evaluated it by the area under the ROC curve (AUROC). Kaplan Meier curves were performed before Cox proportional hazard models. The log-rank test
was used to tell the differences of recurrence statistically. A Cox regression model was used to determine prognostic factors. A difference was considered statistically significant when $p < 0.05$ and in factors compared. When comparing multiple groups, the new $P$ value was considered to be $0.05$/group number.

**Results**

**Baseline characteristics.** Among all patients, 37.96% (1559/4107) of patients and 33.96% (1659/4884) of lesions confirmed with histologically positive central lymph node metastasis (CLNM). A total of 909 males and 3198 females in the study with the male/female ratio of 1:3.52; the age of the patients ranged from 12 to 82 years with a median age of 45.21 years; the diameter of the tumors ranged from 0.1 cm to 8.0 cm with a median diameter of 0.92 cm. The median follow-up time was 45.00 months (range from 24–143.0 months).

**Risk factors for CLNM.** In the univariate analysis, Gender, Age, Tumor size, Lobe dissemination, Psammoma body, Tumor number and Capsule invasion were significantly associated with CLNM ($P < 0.05$), while no significant correlation was found between Bilateral and CLNM ($P > 0.05$) (Table 1). In the multivariate analysis, Male ($P < 0.01$, odds ratio 1.706, 95% CI 1.469–1.981), Age $\leq$ 35 years ($P < 0.01$, odds ratio 2.217, 95% CI 1.893–2.597), Tumor size $> 0.5$ cm ($P < 0.01$, odds ratio 3.154, 95% CI 2.706–3.676), Lobe dissemination (+) ($P < 0.01$, odds ratio 3.027, 95% CI 2.333–3.928), Psammoma body (+) ($P < 0.01$, odds ratio 3.158, 95% CI 1.943–5.132), Multifocality ($P < 0.01$, odds ratio 1.542, 95% CI 1.321–1.800) and Capsule invasion (+) ($P < 0.01$, odds ratio 1.508, 95% CI 1.316–1.728) were independent risk predictors of CLNM (Table 2).

The rate of CLNM increased obviously with the decrease of age in a certain range and there were significant difference in the rate of CLNM between groups with age $\leq$ 25 years, 25 years $< age \leq$ 35 years and 35 years $< age \leq$ 45 years ($P < 0.001$). Besides, the rate of CLNM was found to fluctuate strongly between the group with 25 years $< age \leq$ 35 years, and 35 years $< age \leq$ 45 years (51.29% vs 37.55%) and become relative stable when age $\geq$ 35 years, which indicate that maybe age $= 35$ years could be used as a cut-off point to predictive CLNM. Thus, we

| Central Lymph Node Metastasis in CN0 patients | – | + | Case number | Positive rate | $P$ value |
|---------------------------------------------|---|---|-------------|--------------|----------|
| Gender                                      | – | + | 463 446 909 | 49.06%       | 0.000    |
| Male                                        | – | + | 2085 1113 3198 | 34.80%     | 0.000    |
| Female                                      | – | + | 2085 1113 3198 | 34.80%     | 0.000    |
| Age (years)                                 | – | + | 25 322 339 661 | 51.29%     | 0.000*   |
| $\leq$ 25                                   | – | + | 50 110 160 68.75% | 0.000**   |
| 25–35                                       | – | + | 322 339 661 | 51.29%     | 0.000**   |
| 35–45                                       | – | + | 785 472 1257 | 37.55%     | 0.000**   |
| 45–55                                       | – | + | 880 425 1305 | 32.57%     | 0.000**   |
| 55–65                                       | – | + | 415 165 580 | 28.45%     | 0.000**   |
| $> 65$                                      | – | + | 96 48 144 | 33.33%     | 0.000**   |
| Tumor size (cm)                             | – | + | 1570 322 1892 | 31.67%     | 0.000**   |
| $\leq$ 0.5                                  | – | + | 1094 634 1728 | 36.69%     | 0.000**   |
| 0.5–1.0                                     | – | + | 316 306 622 | 49.20%     | 0.000**   |
| 1.0–1.5                                     | – | + | 113 168 281 | 59.79%     | 0.000**   |
| 1.5–2.0                                     | – | + | 132 229 361 | 63.43%     | 0.000**   |
| Lobe dissemination                          | – | + | 3124 1448 4572 | 31.67%     | 0.000**   |
| Psammoma body                               | – | + | 3198 1593 4791 | 33.25%     | 0.000**   |
| Tumor number                                | – | + | 27 66 93 | 70.97%     | 0.000**   |
| solitary                                    | – | + | 2597 1229 3826 | 32.12%     | 0.000**   |
| Multifocality                               | – | + | 628 430 1058 | 40.64%     | 0.000**   |
| Bilateral                                   | – | + | 2207 1123 3330 | 33.72%     | 0.000**   |
| Capsule invasion                            | – | + | 1988 691 2679 | 25.79%     | 0.000**   |

Table 1. Correlation between Clinical Factors and Central Lymph Node Metastasis(CLNM). *Age $\leq$35 years versus age $>$35 years. ** $\Phi \leq$ 0.5 cm versus $\Phi >$ 0.5 cm.
regroup the patients and found the CLNM rate was significantly higher in the group age ≤ 35 years than age > 35 years (P < 0.01) (Table 1).

Patients were divided into 5 groups based on the maximum diameter of tumor. Significant difference in the rates of CLNM was found between different groups and the rate of CLNM increased obviously with the increase of tumor size. The CLNM rate of the group with Φ < 0.5 cm was significantly lower than other groups. In order to found a cut-off point to predictive CLNM, an ROC analysis was done and the area under the curve was 0.704 (P < 0.01), indicating that Φ = 0.5 cm could be considered a threshold to predict CLNM according to the curve (Fig. 1A).

**Development of risk-scoring model to predict CLNM.** A 14-point risk-scoring model was built to predict the stratified CLNM in PTC patients (Table 3). With the scoring model, the rate of positive CLNM ranged from 16.94% to 100% in order of total score in the PTC patients (Table 4). According to the ROC curve, the AUROC of the model for the prediction of CLNM was 0.672 (95% CI: 0.656–0.688) (P < 0.01) (Fig. 1B), which implies the discriminative power of the model is acceptable. Besides, total score = 4 was selected as the appropriate cut-off point of the model and the patients with total score range from 0–3 were divided into low-risk group of CLN, while the patients with total score range from 4–14 were divided into high-risk group of CLN (average CLNM rate: 17.75%), which implies the discriminative power of the model is acceptable. Besides, total score = 4 was selected as the appropriate cut-off point of the model and the patients with total score range from 0–3 were divided into low-risk group of CLN, while the patients with total score range from 4–14 were divided into high-risk group of CLN (average CLNM rate: 17.75%), while the patients with total score range from 4–14 were divided into high-risk group of CLN (average CLNM rate: 17.75%), while the patients with total score range from 4–14 were divided into high-risk group of CLN (average CLNM rate: 17.75%), while the patients with total score range from 4–14 were divided into high-risk group of CLN (average CLNM rate: 17.75%).

**Predictors of recurrence in patients with PTC.** A total of 4107 patients were followed up and the average follow-up time was 49.90 months (standard deviation: ± 23.91 months) and the median follow-up time was 45 months (range from 24–143 months). One hundred patients (2.43%) were found with recurrence and 25 (0.61%) patients were dead, in which only 9 (0.22%) were attributed to PTC. Thus, we evaluated the disease-free survival instead of overall survival due to the small number of patients with death. COX regression model showed that Tumor size > 0.5 cm (P < 0.01, hazard rate 2.601, 95% CI 1.382–4.896), Lobe dissemination (+) (P < 0.01, hazard rate 2.649, 95% CI 1.630–4.305), Multifocality (P < 0.01, hazard rate 3.070, 95% CI 1.973–4.788) and CLNM (P < 0.01, hazard rate 2.914, 95% CI 1.728–4.912) were risk predictors of recurrence. (Table 5).

|                     | B   | SE  | Sig. | Exp(B) | 95.0% CI | Exp(B) |
|---------------------|-----|-----|------|--------|----------|--------|
| Gender(male vs female) | 0.534 | 0.076 | 0.000 | 1.706   | 1.469    | 1.981  |
| Age(≤ 35 years vs > 35 years) | 0.796 | 0.081 | 0.000 | 2.217   | 1.893    | 2.597  |
| Tumor size (Φ > 0.5 cm vs Φ ≤ 0.5 cm) | 1.149 | 0.078 | 0.000 | 3.154   | 2.706    | 3.676  |
| Lobe dissemination (positive vs. negative) | 1.108 | 0.133 | 0.000 | 3.027   | 2.333    | 3.928  |
| Psammoma body (positive vs. negative) | 1.150 | 0.248 | 0.000 | 3.158   | 1.943    | 5.132  |
| Capsule invasion (positive vs. negative) | 0.411 | 0.069 | 0.000 | 1.508   | 1.316    | 1.728  |
| Bilateral (positive vs. negative) | 0.073 | 0.072 | 0.312 | 1.076   | 0.933    | 1.240  |
| Tumor number (Multifocality vs. Solitary) | 0.433 | 0.079 | 0.000 | 1.542   | 1.321    | 1.800  |
| Constant            | −1.354 | 0.096 | 0.000 | 0.258   |          |        |

**Table 2.** Multivariate logistic regression for central lymph node metastasis. *B*: regression coefficient, *SE*: Standard Error, *Sig*: significance, *Exp(B)*: odds ratio, *CI*: confidence interval.

**Figure 1.** (A) ROC curve of the ability of tumor size to predict the likelihood of metastasis to central lymph nodes. (B) ROC curve of the ability of risk-scoring model to predict the likelihood of metastasis to central lymph nodes.
As was shown above, Tumor size >0.5 cm, Lobe dissemination (+), Multifocality and CLNM were significant risk factors associated with poor outcomes. Thus, we regrouped the patients into five groups according to the number of these risk factors. There were 889 patients with 0-factor, 1364 patients with 1-factor, 1168 patients with 2-factors, 610 patients with 3-factors and 76 patients with 4-factors. There were significant differences in disease-free survival (DFS) rate between the five groups. The DFS rate was highest in 0-factor (99.60% at 143 months) and 1-factors (99.20% at 143 months), lowest in 4-factors group (72.40% at 143 months), and intermediate in 2-factors group (97.10% at 143 months) and 3-factors group (95.10% at 143 months) (Fig. 2). Patients with a greater number of risk factors were usually more vulnerable to recurrence.

**Discussion**

The aim of this study was to evaluate the predictive factors of CLNM and identify risk factors of recurrence in the Han Chinese. There were about 37.96% of PTC patients were proved with CLNM by histopathologic result post-operation, which means that more than one third of the patients would suffer from incomplete treatment if we did not perform prophylactic CLN dissection in PTC patients. The occult metastatic lymph nodes would be remained in the bodies and became one of the most important sources of recurrence. Our data showed that the

---

| Risk score | Negative | Positive | Total | Positive rate |
|------------|----------|----------|-------|---------------|
| 0          | 104      | 20       | 124   | 16.13%        |
| 1          | 70       | 25       | 95    | 26.32%        |
| 2          | 744      | 108      | 852   | 12.68%        |
| 3          | 569      | 168      | 737   | 22.80%        |
| 4          | 230      | 193      | 423   | 45.63%        |
| 5          | 404      | 219      | 623   | 35.15%        |
| 6          | 760      | 436      | 1196  | 36.45%        |
| 7          | 244      | 276      | 520   | 53.08%        |
| 8          | 41       | 84       | 125   | 67.20%        |
| 9          | 32       | 64       | 96    | 66.67%        |
| 10         | 24       | 49       | 73    | 67.12%        |
| 11         | 3        | 11       | 14    | 78.57%        |
| 12         | 0        | 4        | 4     | 100.00%       |
| 13         | 0        | 2        | 2     | 100.00%       |

Table 4. Risk scores and percentage of positive central lymph node metastasis in papillary thyroid carcinoma patients.
recurrence rate of PTC was 2.43% (100 patients) and only 9 were died of PTC during follow-up, which implied a good prognosis of PTC patients. The main reason of recurrence may be due to incomplete CLN dissection or occult lateral cervical lymph node metastasis. Thus, we considered that even in the patients underwent prophylactic CLN dissection, there were still 2.43% of patients suffer from recurrence. Then, there will be a higher rate of recurrence in patients without prophylactic CLN dissection. Then how would be the patients without prophylactic CLN dissection?

Currently, an increasing number of experts supported prophylactic central neck dissection in PTC patients for the reasons as follows: (i) Lymph node metastases have a negative effect on patients’ prognosis. (ii) prophylactic CLN dissection contributes to remove subclinical metastasis and reduce recurrence. (iii) prophylactic CLN dissection does good to the follow-up treatment, including more accurate staging, prognosis evaluation and radioactive iodine therapy. (iv) central neck dissection can be achieved reliably. (v) for central neck recurrence, reoperation leads to elevated morbidity. Prophylactic CLN dissection was also recommended by the American Thyroid Association (ATA) Guidelines for PTC, particularly for patients who have advanced primary tumors (T3 or T4). However, Kim SK et al. suggested that prophylactic central neck dissection may not be proposed in PTC due to the absence of proven benefit and clear evidence of morbidity, for instance temporary vocal cord palsy and temporary hypoparathyroidism. We support the former for the high rate of occult CLNM and its negative effect on recurrence. Besides, as a retrospective study, there was an inevitable serious selection bias in Kim’s work, which may affect the credibility of the results.

It has been wildly accepted that women were more susceptible to PTC. Grebe SK and Hay ID revealed the notable relevance between the morbidity of PTC and estrogen level in women and Fan D et al. considered that estrogen receptor $\alpha$ could promote PTC by improving autophagy in PTC cells, a vital pro-survival catabolic way. An entirety of 909 males and 3198 females in our research in which the male: female ratio (1:3.52) is consistently comparing with our former studies. Moreover, our results showed that the CLNM rate of male (49.06%) was significantly higher than female (34.80%) ($P < 0.01$, odds ratio 1.706), which is inconsistent with our previous research.
The main reason of the discrepancy may be the more extensive sample size of this study. However, in Cox regression analysis, male is not the risk factor of recurrence.

Age has been used as a prognosis predictor in PTC patients for many years and it is one of the most important factors to be considered to identify the PTC patients with high risk or low risk based on the TNM classification. But its role in CLNM was still controversial. Some scholars found no significant diversity in the older cases (age > 45 years) comparing to older cases (age > 45 years) on CLNM. In contrast, Siddiqui S et al. argued that CLNM rate in young group (age ≤ 45 years) was notably higher contrasted to older ones (age > 45 years) in Papillary Thyroid Microcarcinoma (63.4% vs. 36.6%, P = 0.029). Our results supported the latter. 6 groups were divided on the basis of age (per 10 years) for further study and it has been found that the rate of CLNM was apparently inferior to the group whose age ≤ 35 years than those whose age > 35 years (54.69% vs.33.78%, P < 0.01, odds ratio 2.217) and became relative stable when age ≥ 35 years, which indicated that patients with less than 35 years old were more vulnerable to CLNM and age ≥ 35 years maybe could be used as a cut-off point to predict CLNM. Otherwise, no significant correlation was found between age and recurrence.

Some studies reported that patients with tumor size > 3 cm would be more susceptible to recurrence in the lymph node. On U et al. discovered tumor size was highly associated with the number of CLNM. We found that increasing CLNM was related to the enlarging tumor size (P < 0.01) and 0.5 cm was presented as a cut-off point for prediction of CLNM by ROC curve (Fig. 1). This result was incompatible with a previous study suggesting tumor size was independent of CLNM using logistic regression, which may be due to the more extensive sample size in this study than previous. Furthermore, it was found in our study that tumor size exceeding 0.5 cm presented a higher risk of recurrence (P < 0.01).

Capsule invasion was always considered as a symbol of tumor progression and patients with capsule invasion appeared to be more prone to attack and recurrence. Extension involving extrathyroidal was found associate with lower surviving rate and maybe one of the risk factors increasing lymph node metastasis. Extrathyroidal extension was also considered to have a positive effect on the number of CLNM. Our results showed that capsule invasion is one of the independent predictors for CLNM (P < 0.01), while no meaningful correspondence was observed between capsule invasion and recurrence, which indicated that microscopic extent invasion of thyroid capsule may not affect the recurrence of the patients.

Recently, Kim HJ and colleges suggested that an increasing amount of tumor foci was significantly correlated with cervical lymph node metastasis and advanced TNM stage of PTC and the number of tumor foci independently predicted lateral lymph node metastasis. Increased tumor number seemed to be more likely to happen capsular invasion, extrathyroidal extension, and lymph node metastasis. Previous studies showed that psammoma body is beneficial to predict prognosis and adverse clinical biological behavior of PTC. Can N et al. considered that intraglandular dissemination, lateral tubular growth, tumor border and lymphocytic/stromal tumor response, multi-focality, concomitant lymphocytic thyroiditis were easier to have lymph node metastasis. In this study, intraglandular dissemination (+), psammoma body (+) and multifocality were independent risk factors of CLNM and intraglandular dissemination (+) and multifocality may shorten the prognosis of PTC patients.

Subsequently, based on the independent risk factors mentioned above, we developed a risk-scoring model to predict CLNM. It is well known that a predictive model not only enlightens each predictor on the probability of a response from levels of other factors but also provides a quick estimation of the probability from response for individual subjects. This risk-scoring model shows good discriminative power. The average CLNM rate of the patients with score ≥ 4 was significantly higher than the patients with score ≤ 3 (43.50% vs. 17.75%, P < 0.01). The risk-scoring model was very simple and efficient to implement in clinical works and could preliminarily help surgeons to identify high-risk groups in a relatively objective way. With this model, combining with image examinations, surgeons could make a more comprehensive and accurate decision pre/intra-operation to avoid the incomplete treatment in the central compartment. Due to the high-risk of CLNM, we advocated prophylactic CLN dissection in patients with total score ≥ 4 according to the risk-scoring model.

The results of our study showed that Tumor size > 0.5 cm, Lobe dissemination (+), Multifocality and CLNM were significant risk factors for recurrence. The DFS rate of patients having 4-factors was notably more moderate than other groups, indicating that patients with a great deal of risk factors were generally more vulnerable to recurrence and more complete treatment as well as a more frequent follow-up should consider for patients with 4 factors.

However, the present study has some certain limitations, which expects to be extended upon in additional researches. Firstly, as a retrospective study, selection bias is inevitable in this study. Secondly, part of patients had unilateral lesions, who underwent unilateral lobectomy plus isthmusectomy and ipsilateral CLN dissection in this study, while we don't know whether those patients have occult contralateral thyroid tumors. Thirdly, all the patients included were Chinese. It is not certain that the conclusion applies to other races.

**Conclusion**

In summary, more than one third of PTC patients were proved with CLNM in our research, which indicated the generalization of CLNM in PTC. Patients with male, age ≤ 35 years, tumor size > 0.5 cm, Lobe dissemination (+), Psammoma body (+), Multifocality or Capsule invasion (+) were considered more vulnerable to CLNM, and CLNM, Tumor size > 0.5 cm, Lobe dissemination (+) and Multifocality may increase the risk of recurrence and perhaps decrease survival. On this account, according to our model, we suggested that prophylactic CLN dissection could be performed routinely in PTC patients with total score ≥ 4, and more aggressive treatment and more frequent follow-up should be considered for patients with CLNM, Tumor size > 0.5 cm, Lobe dissemination (+) and Multifocality.
Data availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 12 August 2019; Accepted: 2 December 2019; Published online: 20 January 2020

References
1. Falco, J., Dip, F., Quadri, P., de la Fuente, M. & Rosenthal, R. Cutting Edge in Thyroid Surgery: Autofluorescence of Parathyroid Glands. J Am Coll Surg. 223(2), 374–380 (2016).
2. Lundgren, C. I., Hall, P., Dickman, P. W. & Zedénius, J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106(3), 524–531, https://doi.org/10.1002/cncr.21653 (2006).
3. Mazzaferrì, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine. 97(5), 418–428 (1994).
4. Shaha, A. Prognostic factors in papillary thyroid carcinoma and implications of large nodal metastasis. Surgery. 135(2), 237–239 (2004).
5. Kourovas, M. A. et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 136(4), 954–955 (2003).
6. Grebe, S. K. & Hay, I. D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surgical Oncology Clinics of North America. 5(1), 43 (1996).
7. Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 19(11), 1167–1214 (2009).
8. Moreno, M. A. et al. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 137(2), 157–162 (2011).
9. Lim, Y. S. et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 150(1), 116–121 (2011).
10. Patron, Y. et al. Predictive factors for lateral occult lymph node metastasis in papillary thyroid carcinoma. European Archives of Otorhinolaryngol. 270(7), 2095–2100 (2013).
11. Mazzaferrì, E. L., Doherty, G. M. & Steward, D. L. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 17(7), 683–689 (2009).
12. Kim, S. K. et al. Prophylactic Central Neck Dissection Might Not Be Necessary in Papillary Thyroid Carcinoma: Analysis of 11,569 Cases from a Single Institution. J Am Coll Surg. 222(5), 853–864 (2016).
13. Fan, D. et al. Estrogen receptor alpha induces prosurvival autophagy in papillary thyroid cancer via stimulating reactive oxygen species and extracellular signal regulated kinases. J Clin Endocrinol Metab. 100(4), E561–571 (2015).
14. Jiang, L. H. et al. Clinical Characteristics Related to Central Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma: A Retrospective Study of 916 Patients. Int J Endocrinol. 2014, 385787 (2014).
15. Haugen, B. R. et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Archives of Internal Medicine. 26(1), 1 (2015).
16. Koo, B. S. et al. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Annals of Surgery. 249(5), 840–844 (2009).
17. Siddiqui S. et al. Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma. Thyroid Official Journal of the American Thyroid Association. 26(6) (2016).
18. Ito, Y. et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World Journal of Surgery. 31(11), 2085–2091 (2007).
19. Qu, N. et al. Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis. World Journal of Surgery. 16(8), 3361–3363 (2015).
20. Moo, T. A. et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Annals of Surgery. 250(3), 403 (2009).
21. Lin, J. D. et al. Multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine. 6(1), 91–98 (1999).
22. Vassileiadis, I. et al. Papillary thyroid microcarcinoma: clinicopathological characteristics and implications for treatment in 276 patients. European Journal of Clinical Investigation. 42(6), 657–664 (2012).
23. Lee, Y. S. et al. Nodal status of central lymph nodes as a negative prognostic factor for papillary thyroid carcinoma. Journal of Surgical Oncology. 107(7), 777–782 (2013).
24. Kim, H. J. et al. Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma. Head & Neck. 37(5), 650–654 (2015).
25. Tam, A. A. et al. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine. 53(3), 1–10 (2016).
26. Bai, Y. et al. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Modern Pathology. 22(7), 887–894 (2009).
27. Cai, Y. F. et al. The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma: A Large Case-control Study. Medicine. 94(44), e1881 (2015).
28. Can, N. et al. Histopathological Evidence of Lymph Node Metastasis in Papillary Thyroid Carcinoma. Endocrine Pathology. 26(3), 218–228 (2015).

Acknowledgements
This research was supported by National Natural Science Foundation of China(Grant No. 81702644), National Natural Science Foundation of China (Grant No. 81672642), and Ministry of Health P. R. China Foundation for Science Research (WKJ-ZJ-1605).

Author contributions
L.h. Jiang, K.-x. Yin and Q.-l. Wen made major contributions in the preparation of the figures, interpretation of the results and writing of the manuscript. C. Chen provided technical assistance and data processing. M.-h. Ge guided for research and organized the work. Z. Tan reviewed and revised the manuscript.
Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to M.-h.G. or Z.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020

© The Author(s) 2020